Close Menu

NEW YORK – A new study published in Science Translational Medicine this week found that MEK inhibitors in combination with BET inhibitors could be potent against high MYCN-expressing triple negative breast cancer.

The authors of the study hope that their findings will accelerate development of BET inhibitors for TNBC, where there is an unmet need.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.